Opinion
Video
Author(s):
Clinical oncologists present the case of a 62-year-old man with recurrent prostate cancer.
Real-world studies underline safety, efficacy of radium-223 in mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
Radium-223 re-treatment is safe in patients with mCRPC
Dr. Schwen on focal therapies for prostate cancer
Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC
STOPCAP: ARPIs benefit younger patients with mHSPC